May 1, 2026
PERSONAL AND CONFIDENTIAL
Elisabet de los Pinos
Re: Amended & Restated Consulting Agreement
Dear Ms. de los Pinos:
In connection with the termination of your employment with Aura Biosciences, Inc. (the “Company”) effective on April 30, 2026 (the “Termination Date”), you and the Company entered into that certain Consulting Agreement dated as of April 30, 2026 (the “Prior Agreement”). The Company and you now desire to amend, restate, and supersede the Prior Agreement in its entirety. Accordingly, the terms set forth below shall constitute the amended and restated consulting agreement between you and the Company (this “Consulting Agreement”), which, upon execution by both parties, shall amend, restate, and supersede the Prior Agreement in its entirety. Now, therefore, in consideration of the agreements and obligations set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, you and Company hereby agree as follows:
1.Consulting Period; Services; Consideration. Provided you do not revoke and comply with that certain Transition and Release Agreement by and between you and the Company dated April 30, 2026 (the “Release Agreement”), the term of this Consulting Agreement and your services as a consultant for the Company shall commence immediately following the Termination Date and, unless terminated earlier pursuant to Section 6 below, shall continue in effect through the six (6) month anniversary of the Termination Date (such anniversary, the “Outside Date,” and, such period, the “Consulting Period”). During the Consulting Period, you shall provide to the Company the services reasonably requested by the Chief Executive Officer of the Company that relate to the transition of your responsibilities during your employment as Chief Executive Officer (the “Services”), with such Services not to exceed ten (10) hours per month, unless otherwise mutually agreed by you and the Company. As consideration for your agreement to this Consulting Agreement, subject in each case to (i) the terms of the Company’s Amended and Restated 2009 Stock Option and Restricted Stock Plan, 2018 Equity Incentive Plan and 2021 Stock Option and Incentive Plan and the associated award agreements thereunder (collectively, the “Equity Documents”), unless otherwise specified herein, and (ii) you executing, not revoking, and complying with the terms of the Release Agreement, and (iii) complying with the terms of this Consulting Agreement, you shall receive the following benefits, to which you agree you would not otherwise be entitled:
(a)Post-Termination Exercise Period Extension: Notwithstanding anything to the contrary in the Equity Documents, the Company will extend the period of time in which you may exercise any vested options to purchase shares of common stock in the capital of the Company (“Options”) until the earlier of (i) June 30, 2028 and (ii) the original expiration date for the applicable Option, subject to any earlier termination as may be required pursuant to the Equity Documents. You acknowledge that such extension of the post-termination exercise period for the vested Options described herein will cause the Options, if they were intended to qualify as incentive stock options within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended, to be taxable as a nonqualified stock options under U.S. federal tax laws.
(b)Consulting Period Accelerated Vesting: Notwithstanding anything to the contrary in the Equity Documents, your previously granted equity awards (collectively, and including the Options, the “Equity Grants”) that are unvested as of the Termination Date shall vest on an accelerated basis during the Consulting Period as follows: (i) three-sixths (3/6) of the unvested Equity Grants shall vest on